BOTHELL, Wash., April 9, 2008 /PRNewswire-FirstCall/ -- Cardiac Science Corporation (Nasdaq: CSCX), a global leader in advanced cardiac diagnosis, resuscitation, rehabilitation, and informatics products, announced it won a five-year contract from the Australian Defence Force for the initial supply of 170 Powerheart(R) G3 Pro(R) automated external defibrillators (AEDs) and accessories. The sale adds to a string of international wins including a 100-unit delivery to Eastern European military forces and a 300-unit delivery for public access defibrillators for train stations in the Netherlands.
"We are honored to support the service men and women of Australian Defence Force with the durable Powerheart AED G3 Pro," said Kurt Lemvigh, international vice president, Cardiac Science. "Australia's confidence will be rewarded with dependable defibrillation, ease-of-use, data transmission and connectivity, and 3-lead ECG monitoring capabilities."
The G3 Pro provides the industry's first ECG color display, manual override features, multiple rescue capability, and the most advanced technology for rescue professionals' emergency treatment of sudden cardiac arrest. Infrared data communications allow data from the AEDs to be transmitted to a Windows PC, for ready connectivity and event documentation.
Cardiac Science is a leading AED supplier to Australia. Working with the government and key Australian organizations, Cardiac Science created significant awareness for the need for public access defibrillation in the Australian market. Now, a growing number of major corporations deploy Cardiac Science AEDs on a large scale, protecting workplaces against sudden cardiac arrest.
All Powerheart AEDs feature patented Rescue Ready(R) technology to run daily, weekly, and monthly self-tests of battery, internal electronics, software, and pads. Rescue Ready tests differentiate Powerheart devices among AEDs and ensure anytime functionality and shock delivery.
About the Australian Defence Force
The Australian Defence Force (ADF) is the military of Australia. It consists of the Royal Australian Navy, Australian Army, Royal Australian Air Force, and a number of additional joint units. It includes 51,000 full-time active duty personnel and 19,400 reservists, of which 3,500 are deployed in multiple locations across the world including Afghanistan, Sudan, Israel, and Lebanon.
About Cardiac Science
Cardiac Science develops, manufactures, and markets a family of advanced diagnostic and therapeutic cardiology devices and systems, including automated external defibrillators (AEDs), electrocardiograph devices (ECGs), cardiac stress systems and treadmills, Holter monitoring systems, hospital defibrillators, cardiac rehabilitation telemetry systems, and cardiology data management systems (informatics) that connect with hospital information (HIS), electronic medical record (EMR), and other information systems. The Company sells a variety of related products and consumables, and provides a portfolio of training, maintenance, and support services. Cardiac Science, the successor to the cardiac businesses that established the trusted Burdick(R), HeartCentrix(R), Powerheart(R), and Quinton(R) brands, is headquartered in Bothell, Washington. With customers in more than 100 countries worldwide, the company has operations in North America, Europe, and Asia. For information, call 425.402.2000 or visit http://www.cardiacscience.com.
This press release contains forward-looking statements including, but
not limited to, those that infer that Cardiac Science Corporation's future
revenue and profits may grow as a result of sales of defibrillation
products. These statements and their underlying assumptions involve a
number of risks and uncertainties and are not guarantees of future
performance. These are forward-looking statements for purposes of the safe
harbor provisions under the Private Securities Litigation Reform Act of
1995. The words "believe," "expect," "intend," anticipate," variations of
such words, and similar expressions identify forward-looking statements,
but their absence does not mean that the statement is not forward looking.
Actual results may vary significantly from the results expressed or implied
in such statements. Factors that could cause or contribute to such varying
results and other risks that are more fully described in the Annual Report
on Form 10-K filed by Cardiac Science Corporation for the year ended
December 31, 2007. Cardiac Science Corporation undertakes no duty or
obligation to update the information provided herein.
Company Contact: Investor Contact: Media Contact:
Mike Matysik Jenifer Kirtland Christopher Gale
Cardiac Science Corporation EVC Group, Inc. EVC Group, Inc.
Sr. Vice President and CFO (415) 896-6820 (201) 646-5431
(425) 402-2009 (203) 570-4681
|SOURCE Cardiac Science Corporation|
Copyright©2008 PR Newswire.
All rights reserved